Hemophilia Market By Disease Type (Hemophilia A, Hemophilia B, Other Hemophilia Types); By Therapy Type (Factor Replacement Therapy, Non-Factor Replacement & Rebalancing Therapy, Gene Therapy, Bypassing Agents & Adjunctive Therapies); By Treatment Approach (Prophylaxis, On-Demand Treatment, Perioperative Management); By End User (Hemophilia Treatment Centers, Hospitals & Specialty Clinics, Homecare Settings); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Hemophilia Market: From Factor Replacement to Gene Therapy Disruption and the Rise of Multi-Modal Prophylaxis Competition

The Global Hemophilia Market was valued at USD 15.82 billion in 2025 and is projected to reach USD 24.42 billion by 2032, expanding at a CAGR of 6.4% during 2026–2032.

 

Hemophilia is a rare inherited blood disorder in which the blood does not clot properly due to a deficiency of clotting factors, leading to a lifelong risk of excessive bleeding either spontaneously or after injury. The condition is mainly seen in two forms: hemophilia A, caused by a lack of clotting factor VIII, and hemophilia B, caused by a lack of clotting factor IX. Hemophilia A is the larger patient segment; U.S. treatment-center data indicate that approximately 76.5% of patients have hemophilia A and 23.5% have hemophilia B. The CDC estimates that up to 33,000 males are affected by hemophilia in the United States, while just over 40% have severe disease and can require regular preventive treatment.

 

FDA-approved hemophilia treatments include traditional factor replacement therapies such as Advate, Adynovate, Eloctate and Alprolix, which replace deficient clotting factors VIII or IX. Newer non-factor therapies have shifted treatment toward more convenient prophylaxis. Hemlibra is established in hemophilia A, while Alhemo, Hympavzi and Qfitlia extend non-factor treatment across hemophilia A and B populations. Hemgenix provides a one-time gene-therapy option for eligible adults with hemophilia B.

 

The market is shifting away from frequent intravenous factor replacement toward longer-acting factors, subcutaneous non-factor prophylaxis and limited gene-therapy use in eligible adults. Roche's Hemlibra demonstrates the commercial scale of this transition: 2025 sales reached CHF 4.754 billion, up 11% at constant exchange rates, compared with the overall Hemophilia Market CAGR of 6.4% projected for 2026–2032.

 

How Large Is the Addressable Hemophilia Patient Population?

Hemophilia remains rare, but the lifetime treatment requirement makes each diagnosed severe patient commercially important. A large meta-analysis of national registries estimated prevalence at 17.1 cases per 100,000 males for hemophilia A and 3.8 for hemophilia B. Based on these published prevalence rates, hemophilia A represents approximately 81.8% of combined A/B prevalence and hemophilia B about 18.2%, reinforcing why hemophilia A remains the larger patient and treatment segment. These are prevalence shares rather than revenue market shares.

The number of diagnosed hemophilia patients is still much lower than the actual number of people who likely have the disease, especially in many countries. In May 2026, the World Health Assembly passed resolution WHA79.5 to improve care for people with hemophilia and other bleeding disorders. WHO estimates that around 70% of people with hemophilia worldwide remain undiagnosed, leaving future market expansion dependent not only on switching existing patients to newer therapies but also on identifying people currently outside formal treatment systems.

At the same time, patient identification is improving. The World Federation of Hemophilia's 2024 global survey included data from a record 135 countries, and the number of identified patients increased by about 6% compared with the previous survey. As diagnosis systems and registries improve, more patients can enter treatment, particularly in markets where recorded prevalence remains well below that of mature healthcare systems.

The United States has a major structural advantage because hemophilia treatment is organized through specialized centers. CDC's March 2024 Community Counts documentation identified 139 hemophilia treatment centers across the United States and its territories. These centers combine diagnosis, prevention, treatment, education and surveillance, creating infrastructure capable of supporting prophylaxis, inhibitor management and advanced therapies.

Hemophilia C, or factor XI deficiency, and acquired hemophilia represent clinically relevant but commercially smaller niches. Most major hemophilia franchises, reimbursement pathways and recent launches remain concentrated in congenital hemophilia A and B. Acquired hemophilia follows a different treatment pathway because therapy must manage autoimmune inhibitors rather than an inherited FVIII or FIX deficiency.

 

Why Is Preventive Treatment Becoming the Main Commercial Battleground?

For decades, factor VIII and IX replacement concentrates formed the center of hemophilia treatment. They remain critical because factor replacement can prevent bleeding, control acute events and support surgery. The CDC continues to distinguish prophylactic treatment, which prevents bleeding, from episodic treatment given after bleeding occurs.

The commercial importance of prophylaxis comes from recurring lifelong treatment. Extended-half-life products therefore continue to generate strong revenue even as non-factor therapies expand. Sanofi's ALTUVIIIO generated €1.160 billion in 2025, increasing 77.6% at constant exchange rates, after reaching blockbuster status within three years of its U.S. introduction. Sanofi also reported that 85% of Q4 2025 ALTUVIIIO revenue came from the United States, showing how strongly current uptake remains concentrated in the U.S. hemophilia A market.

ALTUVIIIO's growth is also coming partly from treatment switching. Sanofi reported that patients moved to the product from shorter-half-life and older extended-half-life factor therapies as well as from non-factor treatments. The company's hemophilia A factor franchise, combining ALTUVIIIO and Eloctate, generated €387 million in Q4 2025 and grew 35% at CER, with ALTUVIIIO contributing €324 million of that quarterly total.

Sobi continues to invest in factor products including Altuvoct, Elocta and Alprolix, while Takeda maintains Advate, Adynovate and FEIBA. These portfolios indicate that factor replacement is not disappearing. Rather, the Hemophilia Market is dividing between patients remaining on established or longer-acting factor therapy and those moving toward lower-burden non-factor prophylaxis.

Inhibitors add another commercially important treatment segment. Approximately one in five people with hemophilia A and three in 100 with hemophilia B develop antibodies that can reduce the effectiveness of factor concentrates. This smaller but clinically difficult population historically relied heavily on bypassing agents and is increasingly addressed by non-factor therapies able to provide prophylaxis independently of conventional FVIII or FIX replacement.

 

How Are Non-Factor Therapies Reshaping Competition?

Hemlibra established the commercial viability of large-scale subcutaneous non-factor prophylaxis. Roche generated CHF 4.754 billion from Hemlibra in 2025, up 11% at CER. The United States contributed CHF 2.665 billion, equivalent to approximately 56.1% of global Hemlibra revenue, while Europe represented about 21.1%, Japan 7.9% and Roche's International region 14.9%. U.S. sales grew 6%, Europe 10%, Japan 8% and International sales 38%, demonstrating that the franchise is still expanding outside its largest market.

The competitive environment broadened rapidly between late 2024 and 2026. Pfizer's Hympavzi initially entered the U.S. for patients aged 12 years or older with hemophilia A or B without inhibitors. Its subsequent indication expansion into inhibitor populations and younger pediatric patients materially enlarged its addressable segment. The product competes through once-weekly subcutaneous administration, creating a treatment alternative to repeated intravenous factor therapy and other non-factor prophylaxis.

Novo Nordisk's Alhemo similarly expanded from patients with inhibitors into people without inhibitors. Novo Nordisk reported that its overall rare blood disorders business increased 2% at CER in 2025. Within that portfolio, hemophilia A sales increased about 1%, while hemophilia B sales increased 11%, indicating stronger growth in the smaller hemophilia B segment during the year. Alhemo's expanding presence contributed to the company's broader prophylaxis position.

Sanofi's Qfitlia created another competitive category after receiving U.S. approval for patients aged 12 years or older with hemophilia A or B with or without inhibitors. Its broad label and less-frequent subcutaneous dosing allow Sanofi to participate across multiple treatment segments through one therapy. Qfitlia generated only €9 million in 2025, reflecting its March 2025 U.S. launch and early commercialization stage, compared with ALTUVIIIO's €1.160 billion that year.

At launch, Qfitlia carried an annual U.S. list price of approximately $642,000 for most patients. High annual treatment costs mean relatively small changes in patient switching can create meaningful revenue movements, while payer coverage, treatment persistence and demonstrated reduction in administration burden remain important to adoption.

The market is therefore no longer divided simply between factor VIII and factor IX replacement. Competition increasingly reflects administration frequency, inhibitor status, age eligibility, monitoring requirements, bleed control and reimbursement. This favors therapies able to reduce the practical burden of lifelong prophylaxis without creating substantial new clinical or financial barriers.

 

Why Has Gene Therapy Faced Greater Commercial Resistance Than Expected?

Hemophilia initially appeared particularly suitable for gene therapy because a one-time treatment could potentially replace years of recurring prophylaxis. CSL Behring's Hemgenix remains an approved gene therapy for eligible adults with hemophilia B, while NICE has provided a managed-access route for selected patients in England.

Commercial experience has nevertheless shown that regulatory approval does not guarantee widespread uptake. Pfizer ended development and commercialization of Beqvez in February 2025 after limited market uptake. Its approximately $3.5 million U.S. list price illustrated the large upfront expenditure involved even when the treatment is intended to replace years of chronic therapy.

The difficulty became even clearer in hemophilia A. BioMarin generated only $36 million in global Roctavian revenue during 2025, despite sales increasing 38% from $26 million in 2024. That revenue remained small relative to established prophylaxis franchises. BioMarin subsequently decided to withdraw Roctavian after failing to identify a qualified buyer, while recording approximately $240 million in related restructuring charges.

Roctavian, a gene therapy for hemophilia, made only about $36 million in 2025. In comparison, established treatments like Hemlibra and ALTUVIIIO generate billions of dollars each year. This does not mean they are directly competing on equal terms, because they are used in different types of patients and have different pricing and treatment approaches. However, it clearly shows that gene therapies are still used in far fewer patients and have not yet become widely adopted.

Recent events, including the withdrawal of Beqvez and Roctavian, show that gene therapies for hemophilia are facing real challenges in the market, not just in medical effectiveness. These treatments are very expensive upfront, are only suitable for a limited group of patients, require long-term follow-up, and doctors and patients are still uncertain about how long their benefits will last.

At the same time, existing treatments like regular preventive injections are becoming easier to use and more convenient, which makes it harder for gene therapies to replace them.

Because of this, even though Hemgenix (another gene therapy) is an important innovation, gene therapy is still only a small part of the overall hemophilia treatment market and should not be seen as something that will immediately replace standard long-term treatments for most patients.

 

How Are Reimbursement and Procurement Affecting Treatment Adoption?

Hemophilia is a high-cost specialty market in which reimbursement can directly influence therapy adoption. Medicare has adapted its payment system to newer non-factor therapies. In 2025, CMS established Part B treatment pathways for therapies including Alhemo, Qfitlia and Hympavzi and applied the clotting-factor furnishing framework where relevant. This allows newer prophylaxis products to operate within payment systems already familiar to hemophilia providers.

Gene therapy follows a different economic model. Unlike recurring factor or non-factor treatment, multimillion-dollar one-time therapies require payers to manage a large initial cost while evaluating benefits expected to extend over several years. That financing difference helps explain why gene-therapy reimbursement and access can remain more restrictive even after regulatory approval.

NICE's approach to Hemgenix illustrates this difference. Managed access allows eligible adults with moderately severe or severe hemophilia B to receive treatment while further evidence is generated. Such arrangements can reduce payer uncertainty where the therapy cost is incurred immediately but long-term clinical and economic value accumulates over time.

National procurement also remains important for conventional treatments. Australia's National Blood Authority introduced new haemophilia treatment supply arrangements from July 2025 using multiple therapies and manufacturers. In centrally funded markets, national contracts can influence treatment mix rapidly, making tender access and reimbursement status important alongside regulatory approval.

 

Where Are the Largest Untapped Regional Growth Opportunities?

The biggest long-term growth opportunity remains in underdiagnosed and undertreated regions, particularly lower- and middle-income countries. WFH registry evidence has shown substantially lower prophylaxis use in these markets than in mature healthcare systems. This creates a different growth pathway from North America and Western Europe: expansion comes from diagnosing more patients and moving treatment from emergency or on-demand use toward regular prevention.

North America is the most advanced hemophilia market due to strong healthcare infrastructure, specialist treatment centers, and early adoption of high-cost therapies. The U.S. plays a dominant role in innovative drug sales, accounting for about 56% of Hemlibra’s 2025 global revenue and 85% of ALTUVIIIO’s Q4 2025 sales, highlighting its outsized contribution to leading therapies.

Regionally, North America represents roughly 45–50% of the global hemophilia market in 2025, or about USD 7.1–7.9 billion of the total USD 15.82 billion market. Growth is expected to remain steady at around 6.0–6.5% CAGR (2026–2032), supported by continued uptake of non-factor therapies and long-acting factor treatments.

 

Europe combines established prophylaxis with centralized health-technology assessment and pricing negotiations. Hemlibra generated CHF 1.002 billion in Europe during 2025, approximately 21% of its global sales, with regional revenue increasing 10%. Commercial success in Europe therefore remains meaningful but more dependent on negotiated reimbursement and demonstrated comparative value than in the U.S. The Europe Hemophilia Market is estimated at ~USD 4.1 billion in 2025, representing ~26% of the global market, and is projected to grow at a CAGR of ~5.8% during 2026–2032, broadly in line with but slightly below global growth due to pricing pressure and stricter reimbursement frameworks.

 

Asia-Pacific, Latin America, the Middle East and Africa offer a different growth mechanism as registry coverage, diagnostic testing and specialist services improve. Roche's broader International region generated CHF 710 million in Hemlibra revenue in 2025 (accounting for ~14.9% of global Hemlibra sales) and posted 38% CER growth (38% CAGR), representing a market size of CHF 710 million, the fastest geographic growth rate reported for the product that year. This supports the commercial importance of markets beyond North America and Western Europe even though affordability and public funding continue to influence treatment penetration.

 

How Is the Competitive Landscape Changing?

Roche/Genentech

Roche/Genentech holds a strong position in hemophilia A through Hemlibra, its established subcutaneous prophylaxis therapy. Hemlibra generated CHF 4.754 billion in 2025 sales, highlighting the scale of its recurring treatment franchise.

 

Sanofi/Sobi

Sanofi and Sobi compete through ALTUVIIIO, Qfitlia, and established factor therapies. Their portfolio covers both long-acting factor VIII and less-frequent non-factor prophylaxis, helping them serve patients who remain on factor therapy as well as those switching to newer treatment options.

 

Pfizer

Pfizer is expanding its hemophilia presence through Hympavzi, a once-weekly subcutaneous prophylactic therapy. Its June 2026 expansion to patients aged six years and older, including inhibitor populations, broadened the therapy's potential patient base.

 

Novo Nordisk

Novo Nordisk competes through Alhemo and its broader bleeding-disorder portfolio. The 2025 expansion of Alhemo into patients without inhibitors widened its reach across both hemophilia A and B and increased competition in the non-factor prophylaxis segment.

 

CSL Behring

CSL Behring maintains a differentiated position through Hemgenix, a one-time gene therapy for hemophilia B. The withdrawal of competing gene therapies has reduced the number of commercial alternatives, reinforcing Hemgenix's distinct position in this treatment category.

 

Takeda

Takeda remains an important conventional treatment provider through Advate, Adynovate, and FEIBA. Its portfolio covers factor VIII replacement and inhibitor management, supporting patients requiring acute bleeding control, surgical management, or continued conventional factor therapy.

Competition is becoming less dependent on introducing another factor concentrate and more dependent on lowering the burden of lifelong prevention. Roche has demonstrated the revenue potential of large-scale non-factor prophylaxis, while Sanofi's ALTUVIIIO shows that improved factor therapy can also grow substantially faster than the wider Hemophilia Market. Novo Nordisk, Pfizer and Sanofi are simultaneously broadening competition across hemophilia A, hemophilia B and inhibitor populations.

 

Analyst Perspective

The main near-term growth driver is switching within the existing treated hemophilia population. Hemlibra generated CHF 4.754 billion in 2025 (+11% CER), while ALTUVIIIO reached €1.160 billion (+77.6% CER), both outpacing the broader market CAGR of 6.4% (2026–2032). This shows that growth is being driven more by patients changing therapies than by new patient inflow.

Another source of growth is expanded drug labels. Therapies like Hympavzi, Alhemo, and Qfitlia now cover broader patient groups, including those with or without inhibitors and younger patients, increasing competition within the same treated population.

A longer-term opportunity is the large undiagnosed patient pool, especially in lower-access regions. Improving diagnosis and treatment infrastructure could expand the number of patients receiving prophylaxis over time.

However, the market is highly competitive, and uptake is uneven. For example, BioMarin’s Roctavian generated only $36 million in 2025 before being withdrawn, highlighting the challenge gene therapies face against established and improving long-term treatments.

 

Hemophilia Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 15.82 Billion
Revenue Forecast in 2032	USD 24.42 Billion
Overall Growth Rate	CAGR of 6.4% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Disease Type, By Therapy Type, By Treatment Approach, By End User, By Geography
By Disease Type	Hemophilia A, Hemophilia B, Other Hemophilia Types
By Therapy Type	Factor Replacement Therapy, Non-Factor Replacement & Rebalancing Therapy, Gene Therapy, Bypassing Agents & Adjunctive Therapies
By Treatment Approach	Prophylaxis, On-Demand Treatment, Perioperative Management
By End User	Hemophilia Treatment Centers, Hospitals & Specialty Clinics, Homecare Settings
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, Switzerland, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Growing adoption of prophylactic treatment, increasing shift toward non-factor therapies, rising demand for long-acting clotting factor products, expansion of gene therapy options, improving diagnosis and treatment access in emerging markets
Customization Option	Available upon request